Please wait while we load the requested 10-Q report or click the link below:
MIRAGEN THERAPEUTICS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
|||New MRG-106 Phase 1 cutaneous T-cell lymphoma clinical trial data released|
|||Expansion of the MRG-106 trial to include additional potential indications|
|||Two new independent members added to its Board of Directors|
|||Conference call and webcast today at 4:30 p.m. ET|
BOULDER, CO, August 11, 2017 (GLOBE NEWSWIRE) miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced second quarter 2017 financial results and provided a corporate update.
The second quarter of 2017 has been marked by a number of important development milestones as we position the company for additional clinical opportunities, said miRagen President and Chief Executive Officer, William S. Marshall, Ph.D. In addition to reporting positive new interim Phase 1 clinical trial data underscoring our belief in the potential of the MRG-106 program, we completed our MRG-201 Phase 1 clinical trial and established a potential path forward for expanding both development programs into additional indications. The results generated in both clinical trials represent significant strides forward in execution of our foothold clinical development strategy. We believe that the continued application of the foothold clinical approach may allow us to expand opportunities for our microRNA targeted therapeutic candidates in the future.
Business Highlights and Update
|||Reported new interim MRG-106 Phase 1 clinical trial results, and announced plans to expand the program to include additional potential indications: New interim results from the Companys ongoing Phase 1 clinical trial of MRG-106 in subjects with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2017. Eighteen of nineteen subjects (95%), independent of administration route, showed improvement in either the individual lesion or total skin disease as measured by maximal change in either Composite Assessment of Index Lesion Severity or modified Severity Weighted Assessment Tool (mSWAT), respectively.|
The following information was filed by Miragen Therapeutics, Inc. (MGEN) on Friday, August 11, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Miragen Therapeutics, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Miragen Therapeutics, Inc..